<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445250</url>
  </required_header>
  <id_info>
    <org_study_id>004253</org_study_id>
    <nct_id>NCT00445250</nct_id>
  </id_info>
  <brief_title>The Role of Calcipotriol as Radioprotector of Skin</brief_title>
  <official_title>Phase 2 Study of the Role of Calcipotriol as Radioprotector of Skin in Women Receiving Radiotherapy Treatment to the Breast.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Examining the hypothesis that protecting keratinocytes by calcipotriol can prevent in-vivo&#xD;
      cutaneous side effect in patients receiving radiotherapy to the breast.&#xD;
&#xD;
      To check the connection between the skin effect of radiotherapy and different parameters&#xD;
      including diseases such as diabetes and lupus, use of medications, allergies, weight, habits,&#xD;
      size of the irradiated breast, previous chemotherapy treatment and exposure to sunlight.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY PROTOCOL&#xD;
&#xD;
      Fifty women diagnosed with breast cancer planned to receive adjuvant radiotherapy, will&#xD;
      participate in the study. About 15 minutes after receiving the daily radiation dose fraction,&#xD;
      a cream containing an active vitamin D analogue will be applied to half of the breast with&#xD;
      inspection of a nurse. The other half of the breast will have a standard cream applied .&#xD;
      During the days that radiotherapy is not administered the standard cream will be applied to&#xD;
      both halves of the breast in a case of strong reaction to radiotherapy (e.g. strong erythema,&#xD;
      painful tenderness etc.)The adverse skin effects will be assessed according to the following&#xD;
      criteria:&#xD;
&#xD;
        1. . an assessment by a physician and a nurse according to the RTOG score (6).&#xD;
&#xD;
           As follows:&#xD;
&#xD;
           Grade 0 - no reaction. Grade 1 - light erythema dry peeling, decrease in sweat&#xD;
           production. Grade 3 - extensive moist peeling, pitting edema. Grade 4 - ulcers, bleeding&#xD;
           and necrosis.&#xD;
&#xD;
        2. . A questionnaire to each patient regarding the efficacy and safety of the cream.&#xD;
&#xD;
        3. . Number of interruption of radiotherapy treatment. The assessment will be done each&#xD;
           week during radiotherapy treatment and weekly for three weeks following the completion&#xD;
           of radiotherapy treatment.&#xD;
&#xD;
      Safety report will be sent to the local independent ethics committee after the examination of&#xD;
      the first ten patients.&#xD;
&#xD;
      The protective effect of the cream containing calcipotriol will be compared to the standard&#xD;
      treatment and analyzed statistically using the parameters mention above. The relation between&#xD;
      the background disease, medications, allergies, weight, habits, size of the irradiated&#xD;
      breast, sun exposure, previous chemotherapy treatment and exposure to sunlight and the skin&#xD;
      reaction will be evaluated.&#xD;
&#xD;
      INCLUSION CRITERIA&#xD;
&#xD;
        1. . Age ranging from 18 to 75.&#xD;
&#xD;
        2. . Confirmed histological diagnosis of Breast cancer.&#xD;
&#xD;
        3. . Radiotherapy treatment to the breast following lumpectomy.&#xD;
&#xD;
      EXCLUSION CRITERIA&#xD;
&#xD;
        1. . Scleroderma.&#xD;
&#xD;
        2. . An extremely large breast. Interfiled above 25 cm.&#xD;
&#xD;
        3. . Prior radiotherapy to the same breast, radiotherapy to the contra lateral breast is&#xD;
           not a contraindication.&#xD;
&#xD;
        4. . Mastectomy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of radiodermatitis</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects of Calcipotriol</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Radiodermatitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ranging from 18 to 75.&#xD;
&#xD;
          2. Confirmed histological diagnosis of Breast cancer.&#xD;
&#xD;
          3. Radiotherapy treatment to the breast following lumpectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Scleroderma.&#xD;
&#xD;
          2. An extremely large breast. Interfiled above 25 cm.&#xD;
&#xD;
          3. Prior radiotherapy to the same breast, radiotherapy to the contra lateral breast is&#xD;
             not a contraindication.&#xD;
&#xD;
          4. Mastectomy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eyal Fenig, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eyal Fenig, M.D.</last_name>
    <phone>97239377964</phone>
    <email>efenig@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ofer Purim, M.D.</last_name>
    <phone>97239377973</phone>
    <email>oferp@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tiqva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Eyal Fenig, M.D.</last_name>
      <phone>97239377964</phone>
      <email>efenig@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Ofer Purim, M.D.</last_name>
      <phone>97239377973</phone>
      <email>oferp@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Eyal Fenig, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ofer Purim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amir Abramovich, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2007</study_first_posted>
  <last_update_submitted>March 7, 2007</last_update_submitted>
  <last_update_submitted_qc>March 7, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2007</last_update_posted>
  <keyword>Calcipotriol</keyword>
  <keyword>Breast</keyword>
  <keyword>Cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Radiodermatitis in Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcipotriene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

